Kidney Cancer Drugs Market is Witnessing Rapid Growth with Pfizer and Merck KGaA Receiving the U.S. FDA Approval for immunotherapy Bavencio (avelumab) with Inlyta (axitinib) for advanced renal cell carcinoma (RCC)
Kidney cancer is cancer that arises within the kidneys. Renal cell malignant neoplastic disease (RCC), additionally referred to as excretory organ cell cancer or excretory organ cell glandular carcinoma, is that the commonest sort of urinary organ cancer concerning nine out of ten urinary organ cancers are excretory organ cell carcinomas. Growing prevalence of kidney cancer or renal cancer is expected to drive growth of the global kidney cancer drugs market. According to the American Cancer Society, around 76,080 new cases of kidney cancer, which is 48,780 in men and 27,300 in women, are estimated to be diagnosed in 2021 in the U.S. Furthermore, around 13,780, which is 8,790 men and 4,990 women, are estimated to die from this disease in 2021. According to the World Cancer Research Fund, Belarus had the highest rate of kidney cancer in 2018, followed by Latvia. Such a high incidence of kidney cancer has increased the demand for relevant medications and treatment options. Some dr...